World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Dr T.J Von Oertzen - Consultant Neurologist and Epileptologist (MD., F.R.C.P.)

Dr. von Oertzen studied medicine at Rheinische-Friedrich-Wilhelm University, Germany and completed his final year at University College of London in 1995. He was supervising consultant in Europe's largest centre for presurgical evaluation in epilepsy, Department of Epileptology, at the University of Bonn where he gained major experience in all aspects of blackouts, epilepsy, non epileptic attack disorders and other conditions. Dr. von Oertzen is fully trained in Neurophysiology, particularly in EEG (electroencephalogram recording of brainwaves) of both surface and intracranial recordings.

Dr. von Oertzen has been appointed as the lead clinician for the epilepsy service at the Atkinson Morley Neuroscience Centre, St George's Hospital, since 2004. At present, he is holding specialist clinics for first fits and blackouts, complex cases and people with drug refractory epilepsy including pre-surgical assessment. He holds an Honorary Senior Lecturer post at St George's University of London is also honorary Consultant Neurologist at Kingston Hospital.

Dr. von Oertzen has presented clinical and research data on national and international conferences. He has frequently published in medical journals and contributed to definite books about epilepsy. He is involved in raising awareness for epilepsy and providing continuous medical education for medical professionals.

Back to experts

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more